MorphoSys AG (ETR:MOR) has received a consensus recommendation of “Hold” from the seven analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is €119.86 ($139.37).

Several analysts recently issued reports on MOR shares. Goldman Sachs Group set a €114.00 ($132.56) target price on MorphoSys and gave the stock a “neutral” rating in a research report on Tuesday, November 19th. Royal Bank of Canada set a €130.00 ($151.16) price target on MorphoSys and gave the stock a “buy” rating in a research note on Tuesday, November 19th. Deutsche Bank set a €129.00 ($150.00) price objective on shares of MorphoSys and gave the company a “buy” rating in a report on Friday. JPMorgan Chase & Co. set a €130.00 ($151.16) price objective on shares of MorphoSys and gave the company a “buy” rating in a research report on Monday, November 18th. Finally, Berenberg Bank set a €145.00 ($168.60) target price on shares of MorphoSys and gave the stock a “buy” rating in a report on Wednesday, December 4th.

ETR MOR opened at €120.40 ($140.00) on Monday. MorphoSys has a 12 month low of €79.70 ($92.67) and a 12 month high of €118.90 ($138.26). The stock has a market cap of $3.80 billion and a price-to-earnings ratio of -39.58. The company’s 50 day moving average is €102.88 and its two-hundred day moving average is €99.16. The company has a current ratio of 7.80, a quick ratio of 7.63 and a debt-to-equity ratio of 9.78.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.

Read More: How is a management fee different from a performance fee?

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.